Metformin increases endogenous glucose production in non-diabetic individuals and individuals with recent-onset type 2 diabetes.
Autor: | Gormsen LC; Department of Nuclear Medicine & PET Centre, Aarhus University Hospital, Aarhus, Denmark., Søndergaard E; Department of Endocrinology, Aarhus University Hospital, Aarhus, Denmark.; Danish Diabetes Academy, Odense University Hospital, Odense, Denmark., Christensen NL; Department of Nuclear Medicine & PET Centre, Aarhus University Hospital, Aarhus, Denmark., Brøsen K; Department of Pharmacology, Odense University Hospital, Odense, Denmark., Jessen N; Department of Clinical Pharmacology, Aarhus University Hospital, Aarhus, Denmark. Niels.Jessen@biomed.au.dk.; Department of Biomedicine, Aarhus University, Aarhus, Denmark. Niels.Jessen@biomed.au.dk.; Steno Diabetes Center Aarhus, Aarhus University Hospital, DK 8200, Aarhus, Denmark. Niels.Jessen@biomed.au.dk., Nielsen S; Department of Endocrinology, Aarhus University Hospital, Aarhus, Denmark.; Steno Diabetes Center Aarhus, Aarhus University Hospital, DK 8200, Aarhus, Denmark. |
---|---|
Jazyk: | angličtina |
Zdroj: | Diabetologia [Diabetologia] 2019 Jul; Vol. 62 (7), pp. 1251-1256. Date of Electronic Publication: 2019 Apr 11. |
DOI: | 10.1007/s00125-019-4872-7 |
Abstrakt: | Aims/hypothesis: Metformin is the endorsed first-line glucose-lowering drug for treating patients with type 2 diabetes but despite more than 50 years of use, no consensus has been reached on its mechanisms of action. In this study, we investigated the glucose-lowering effects of metformin in individuals with type 2 diabetes and non-diabetic individuals. Methods: We performed a randomised, placebo-controlled trial in 24 individuals with recent-onset type 2 diabetes (diabetes duration 50 [48] months) who had good glycaemic control (HbA Results: One participant from the CONT group withdrew due to intolerable gastrointestinal side-effects and was excluded from analysis. As expected, metformin treatment lowered fasting plasma glucose (FPG) in the MET group (~1.5 mmol/l, p < 0.01), whereas no effect was observed in the PLA and CONT groups. Body weight and composition did not change in any of the groups. In both of the metformin-treated groups (MET and CONT), basal glucose R Conclusions/interpretation: Ninety days of metformin treatment resulted in similar increases in EGP and glucose R Trial Registration: ClinicalTrials.gov NCT01729156 FUNDING: This study was supported by grants from The Danish Council for Independent Research | Medical Sciences, Aase Danielsen Fund, the Novo Nordisk Foundation, the Danish Diabetes Association and the Danish Diabetes Academy supported by the Novo Nordisk Foundation. |
Databáze: | MEDLINE |
Externí odkaz: |